Encysive Pharmaceuticals is undergoing a major shakeup, replacing its CEO, laying off 70% of the work force and cutting its expenses. The restructuring was undertaken following the company's failure to get approval for its pulmonary hypertension drug, Thelin. There are questions whether Thelin is currently valuable enough to attract suitors to Encysive if the board puts the company up for sale.

Full Story:

Related Summaries